Janus kinase inhibition in induction treatment of anti‐MDA5 juvenile dermatomyositis‐associated rapidly progressive interstitial lung disease

Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients

(2020) Yuhui Li et al.   Frontiers in Medicine

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis

(2020) Hanna Kim et al.   ANNALS OF THE RHEUMATIC DISEASES

Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review

(2020) Zhongxun Yu et al.   RHEUMATOLOGY

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis

(2019) Charalampia Papadopoulou et al.   BRAIN

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis

(2019) Sara Sabbagh et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib

(2019) Sara Sabbagh et al.   BRAIN

OUP accepted manuscript

(2018)   BRAIN

Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

(2012) T. Gono et al.   RHEUMATOLOGY